Nyrada Inc (ASX: $NYR) Brain Injury Program Update

Nyrada Inc (ASX: $NYR) provided an update on its Brain Injury program, reporting the completion of rat CNS testing under Good Laboratory Practice (GLP) conditions for its lead Brain Injury drug candidate, NYR-BI03. The additional study further supported the safety and tolerability of NYR-BI03, positioning the company on track to commence its first in-human Phase I clinical trial for NYR-BI03 in late CY2024.

Executive Commentary on Progress and Future Plans

Nyrada is pleased to announce the satisfactory completion of rat CNS testing for NYR-BI03 under GLP conditions. This milestone further validates the safety and tolerability of our lead Brain Injury drug candidate. We are committed to continuing to report on the remaining GLP study results and are excited to be on track to commence our first in-human Phase I clinical trial for NYR-BI03 in late CY2024. The positive results from the preclinical stroke study earlier this year, showing a statistically significant level of neuroprotection, have reinforced our confidence in the potential of NYR-BI03 as a neuroprotection treatment for traumatic brain injury and stroke.

Summary of Nyrada Inc's Brain Injury Program Update

Nyrada Inc (ASX: $NYR) provided an update on its Brain Injury program, highlighting the completion of rat CNS testing under GLP conditions for its lead Brain Injury drug candidate, NYR-BI03. The additional study further supported the safety and tolerability of NYR-BI03, positioning the company on track to commence its first in-human Phase I clinical trial for NYR-BI03 in late CY2024. The Company's focus on developing a first in class neuroprotection treatment for traumatic brain injury and stroke has shown promising results, with the preclinical stroke study earlier this year demonstrating a statistically significant level of neuroprotection. Nyrada remains dedicated to advancing its programs and aims to address significant unmet clinical needs in the market sectors it targets.